METOPROLOL SUCCINATE Drug Patent Profile
✉ Email this page to a colleague
When do Metoprolol Succinate patents expire, and when can generic versions of Metoprolol Succinate launch?
Metoprolol Succinate is a drug marketed by Accord Hlthcare, Actavis Elizabeth, Actavis Labs Fl Inc, Alkem Labs Ltd, Cipla, Dr Reddys Labs Ltd, Granules, Hetero Labs Ltd Iii, Lupin, Mylan Pharms Inc, Nesher Pharms, Novast Labs, Pharmadax Inc, Prinston Inc, Reddys, Sandoz, Sunshine, Visum Pharm, Wockhardt, Yichang Humanwell, Zhejiang Jutai Pharm, and Zydus Pharms. and is included in twenty-seven NDAs.
The generic ingredient in METOPROLOL SUCCINATE is metoprolol succinate. There are sixty drug master file entries for this compound. Forty-eight suppliers are listed for this compound. Additional details are available on the metoprolol succinate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Metoprolol Succinate
A generic version of METOPROLOL SUCCINATE was approved as metoprolol succinate by ACTAVIS LABS FL INC on August 3rd, 2009.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for METOPROLOL SUCCINATE?
- What are the global sales for METOPROLOL SUCCINATE?
- What is Average Wholesale Price for METOPROLOL SUCCINATE?
Summary for METOPROLOL SUCCINATE
US Patents: | 0 |
Applicants: | 22 |
NDAs: | 27 |
Finished Product Suppliers / Packagers: | 43 |
Raw Ingredient (Bulk) Api Vendors: | 67 |
Clinical Trials: | 58 |
Patent Applications: | 1,415 |
Drug Prices: | Drug price information for METOPROLOL SUCCINATE |
Drug Sales Revenues: | Drug sales revenues for METOPROLOL SUCCINATE |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for METOPROLOL SUCCINATE |
What excipients (inactive ingredients) are in METOPROLOL SUCCINATE? | METOPROLOL SUCCINATE excipients list |
DailyMed Link: | METOPROLOL SUCCINATE at DailyMed |
Recent Clinical Trials for METOPROLOL SUCCINATE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
VA Office of Research and Development | Phase 3 |
Cytokinetics | Phase 3 |
Yang I. Pachankis | Phase 4 |
Pharmacology for METOPROLOL SUCCINATE
Drug Class | beta-Adrenergic Blocker |
Mechanism of Action | Adrenergic beta-Antagonists |
Anatomical Therapeutic Chemical (ATC) Classes for METOPROLOL SUCCINATE
US Patents and Regulatory Information for METOPROLOL SUCCINATE
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Wockhardt | METOPROLOL SUCCINATE | metoprolol succinate | TABLET, EXTENDED RELEASE;ORAL | 090615-003 | Jul 22, 2010 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
Mylan Pharms Inc | METOPROLOL SUCCINATE | metoprolol succinate | TABLET, EXTENDED RELEASE;ORAL | 202033-004 | Dec 15, 2011 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
Hetero Labs Ltd Iii | METOPROLOL SUCCINATE | metoprolol succinate | TABLET, EXTENDED RELEASE;ORAL | 205541-003 | Nov 6, 2020 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
Novast Labs | METOPROLOL SUCCINATE | metoprolol succinate | TABLET, EXTENDED RELEASE;ORAL | 204106-004 | Feb 6, 2018 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
Sandoz | METOPROLOL SUCCINATE | metoprolol succinate | TABLET, EXTENDED RELEASE;ORAL | 076969-003 | Mar 20, 2008 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |